The Fulham Shore Share Discussion Threads

[gimeabreak] 20/3/2008 09:23

Well ansc
Looks like its you and me holding this company up as I bought 53000 yesterday I think we deserve a medal for bravery.

[ansc] 19/3/2008 17:32

It's worth remembering as well that during March and April last year, just over 49 mil shares were placed with institutions and the like at a price of 4.25p compared with today's 2.5p. Apart from the temporary setback caused by bedding-in Unicus, has any significant deterioration in trading taken place since then? If it has, the market should have been informed by now seeing as FUL's financial year ended three weeks ago.

On that basis, I was rash enough to add another 100k this morning at the said 2.5p. A fool and his money.....

[garth] 19/3/2008 11:35

Forecast earnings for 2008 at 0.5p

You can currently buy at or below 2.5p

Thats a pe of 5

From the finals:

"Conclusion
The operating profit from continuing operations of #408,000 (2006: #77,000) is
in line with expectations and Unicus, having now recovered from some initial
integration issues, is trading profitably. The Board is further encouraged by
the strengthened order book since the year end."

22.01.08
"LONDON (Thomson Financial) - Fulcrum Pharma PLC said finance director
Geoffrey Smith has bought 500,000 shares in the company at 3.5 pence each,
raising his holding to around 3.73 mln shares, or about 2.1 pct"

DYOR.

G.

[coincall] 18/3/2008 20:52

2p or not 2p, that is the question.

[platts] 18/3/2008 20:52

someone wants to get out of this failed company-look at the chart.

[gimeabreak] 18/3/2008 20:30

To bye or not to buy very tempting in both respects

[scruff1] 18/3/2008 19:38

fulcrum ticks down after tick up on ceo appointment!

[ansc] 11/3/2008 10:33

Prior to joining CuraGen Corp. (a biopharmaceutical oncology company), where he's worked for the last two years as CEO (and taken from their website):

'During the past four years Dr. Armstrong has applied his considerable skills at smaller technology and biotechnology companies where he successfully raised capital, licensed products and advanced pipelines. Dr. Armstrong was Chief Executive Officer of Phoqus, a private drug delivery company, Chief Executive Officer of Provensis, a company developing treatments for varicose veins, and most recently Chief Executive Officer of Bioaccelerate, a drug development company utilizing a novel business model for the acquisition and advancement of potential drug candidates. Dr. Armstrong was appointed to the CuraGen Board of Directors in 2005, and will continue to serve as a member and will become a Member of the Board of 454 Life Sciences, a majority-owned subsidiary of CuraGen. Dr Armstrong will continue to serve on the Board of Directors of Avidex, Ltd, Oxford, UK.'

I hope CuraGen's share price performance over the past year is not a reflection of Dr. Armstrong's ability. From a high point of $4.17, their share price is presently languishing at just $0.65!

[scruff1] 10/3/2008 07:37

Any views on the RNS?

[ansc] 02/3/2008 11:36

Personally, scruff1, I've found the time to get worried is when directors (especially their FD!) sell a company's shares rather than buy them. During the past year, i.e. since the acquisition of Unicus which (imo) has been the cause of the sp's current downturn, Mr Smith has acquired 800k shares at prices of 3.25 and 3.5p compared to last week's buying price of 3.1p. I've met one or two FDs in my time and 99.9% of them have been tight-fisted when it came to their own money even when they've appeared sometimes to be fairly profligate with that of the company's.

As I wrote earlier, only time will tell whether or not our man turns out to be a 'numpty' but I've paid my money, having been prepared to give him a chance!

[scruff1] 01/3/2008 19:29

garth
agreed. Like I posted some time ago they were doing well and then this. If they can't perk up when they are doing ok what happens when there is a real set back?
Director bought 1/2m at 3.5 the other week. He's just under 30% down. Big loss in such a short time. Maybe that's the problem - not sharp enough at the top.

[garth] 29/2/2008 21:31

Scruff, cf a chemicals, tech & banking stock. Over a 6 month period FUL have outperformed. That may to some extent be due to good visibility re. the Japanese business.

[ansc] 24/2/2008 10:48

I can not see what has changed since the AGM to warrant this currant share price weakness, other than the panicky sentiment affecting the overall market, but it's worth remembering that the company is expanding rapidly and we all know that expansion sometimes comes at a cost.

Bearing in mind that the FD was confident enough to pay 3.5p each for his last 300k shares purchase just over a month ago, I took the opportunity to nab another 100k at the (apparently) ludicrous price of 2.875p last Thursday. Time will tell whether it was either a smart move or that I need immediate certification!

[garth] 23/2/2008 19:51

If you take their performance since the autumn they've outperformed very many other AIM companies......

[scruff1] 23/2/2008 15:18

g a b
ditto. This was beginning to look up. Something must be the reason for the change

[gimeabreak] 23/2/2008 09:32

Really don't know where this company is going, for someone like me who has been with them for year living in hope I'm either a shrewd investor or a complete idiot, from past performance of my investing no way could anybody call me shrewd.

[scruff1] 22/2/2008 20:23

Talking to myself I know but an all time end of week low. Looking like yet another promising AIM corpse

[scruff1] 01/2/2008 19:36

RNS caused an increase in volume though be it ever so slight!!

[scruff1] 22/1/2008 21:06

Had a big effect annit!

[welsheagle] 22/1/2008 07:18

Fulcrum Pharma Director/PDMR Shareholding




RNS Number:2389M
Fulcrum Pharma PLC
22 January 2008


FULCRUM PHARMA PLC

("the Company")

Director Shareholding

The Company has been informed that Geoffrey Smith, Finance Director, yesterday
bought 500,000 ordinary shares in the Company at a price of 3.5p per share.

As a result, Mr Smith now holds 3,732,744 ordinary shares, representing
approximately 2.1% per cent of the current issued share capital of the Company

[shamster] 10/1/2008 14:45

I'd agree. It is often the case that a founder is not the right man to head up a company so to step down and concentrate on his strength seems very wise. Also, at just over £4 million, I wouldn't say that Fulcrum rates as a large company yet so this decision signals the intention to grow the company substantially.

[buggy] 10/1/2008 13:43

Personally this is a great news. It is clear that the current CEO do not have the necessary experience to take the company forward.

Credit must however be given where it is due. Not many CEO admit that they have reached to a point where they are clearly struggling.

[em2481] 10/1/2008 13:15

Any thoughts on today's announcement?

[unionhall] 30/11/2007 20:24

Correct masrscb9.

ADVFN don't keep their figures up to date.

For what it is worth I always check the latest RNS referencing a new shareholder or placement. The RNS will invariably give either the total number of shares in issue or it can be calculated from the % ascribed to the new holder.

(having been caught out by ADVFN before...)